Abstract
Background
We report a case of Graves’ ophthalmopathy (GO) developed after the administration of interferon-α for chronic hepatitis C.
Methods
The GO was treated with lanreotide.
Results
A 47-year-old female patient presented with euthyroid GO with spontaneous retrobulbar pain, eyelid edema, conjunctival injection and eyelid retraction of the right eye and conjunctival injection of the left eye 6 months after administration of interferon-α for chronic hepatitis C. Orbital computed tomography revealed no involvement of extraorbital muscles and no increase in retrobulbar adipose tissue. Only soft tissue was involved. These symptoms subsided after 12 weeks of lanreotide treatment, except right eyelid retraction, which, however, disappeared later during follow-up.
Conclusion
The use of interferon-α may be complicated by GO and lanreotide might be considered for GO if patients cannot accept steroid therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chang TC, Kao CSC, Huang KM (1992) Octreotide and Graves’ ophthalmopathy and pretibial myxoedema. Br Med J 304:158
Chang TC, Yao WC, Chang CC (1992) Octreotide and urinary glycosaminoglycan in Graves’ disease. Br Med J 304:1444
Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF (1988) An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24:1299–1303
Huet D, Entremont A, Hautecouverture M (2000) Basedow’s disease and interferon for hepatitis C. Recurrence as Basedow’s ophthalmopathy after interferon reintroduction. Presse Med 29:82
Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolis G (1997) Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 136:416–422
Kuno M, Mimori A, Fujii T, Takeda A, Masuyama J, Yoshio T, Minota S, Kano S (1996) Histiocytic cytophagic panniculitis which developed during interferon-alpha therapy. Intern Med 35:115–118
Matsuo T, Takabatake R (2002) Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm 10:299–304
Metcalfe RA, Weetman AP (1994) Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 40:67–72
Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA (2000) Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol 25:63–71
Pasquali D, Notaro A, Bonavolonta G, Vassallo P, Bellastella A, Sinisi AA (2002) Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab 87:5125–5129
Rubio JE Jr, Charles S (2003) Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina 23:546–548
Sylvestre DL, Disston AR, Bui DP (2003) Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 10:467–470
Vardizer Y, Linhart Y, Loewenstein A, Garzozi H, Mazawi N, Kesler A (2003) Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 23:256–259
Villanueva RB, Brau N (2002) Graves’ ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid 12:737–738
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Su, DH., Chang, YC., Liao, SL. et al. Lanreotide treatment in a patient with interferon-associated Graves’ ophthalmopathy. Graefe's Arch Clin Exp Ophthalmol 243, 269–272 (2005). https://doi.org/10.1007/s00417-004-1012-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-004-1012-x